Aurinia Pharmaceuticals Inc. – TSX:AUP.TO

Aurinia Pharmaceuticals stock price today

CAD 16.76
Financial Health
0
1
2
3
4
5
6
7
8
9

Aurinia Pharmaceuticals stock price yearly change

-21.54%
year

Aurinia Pharmaceuticals key metrics

Market Cap
N/A
Enterprise value
2.03B
P/E
-11.44
EV/Sales
35.35
EV/EBITDA
-13.40
Price/Sales
37.31
Price/Book
6.46
PEG ratio
-0.67
EPS
-1.23
Revenue
57.59M
EBITDA
-151.89M
Income
-154.00M
Revenue Q/Q
22727.58%
Revenue Y/Y
18011.00%
Profit margin
-267.41%
Oper. margin
-244.89%
Gross margin
38.18%
EBIT margin
-244.89%
EBITDA margin
-263.74%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Aurinia Pharmaceuticals stock price history

Aurinia Pharmaceuticals stock forecast

Aurinia Pharmaceuticals financial statements

Aurinia Pharmaceuticals Inc. (TSX:AUP.TO): Profit margin
Sep 2020 29K -34.06M -117462.07%
Dec 2020 50.03M -22.55M -45.08%
Mar 2021 914K -50.37M -5511.93%
Jun 2021 6.62M -47.01M -710.12%
Aurinia Pharmaceuticals Inc. (TSX:AUP.TO): Earnings per share (EPS)
2020-03-05 -0.18 -0.78
2020-05-14 -0.24 -0.15
2020-08-11 -0.25 -0.26
2020-11-10 -0.22 -0.28
Aurinia Pharmaceuticals Inc. (TSX:AUP.TO): Debt to assets
Sep 2020 461750000 62.90M 13.62%
Dec 2020 463661000 55.91M 12.06%
Mar 2021 417078000 46.85M 11.23%
Jun 2021 386268000 54.01M 13.98%
Aurinia Pharmaceuticals Inc. (TSX:AUP.TO): Cash Flow
Sep 2020 -30.28M -142.63M 189.25M
Dec 2020 5.45M 16.89M 1.24M
Mar 2021 -53.54M -67.24M 5.02M
Jun 2021 -37.97M 1.67M 1.27M

Aurinia Pharmaceuticals alternative data

Aurinia Pharmaceuticals Inc. (TSX:AUP.TO): Employee count
Aug 2023 294
Sep 2023 294
Oct 2023 294
Nov 2023 294
Dec 2023 294
Jan 2024 294
Feb 2024 294
Mar 2024 294
Apr 2024 294
May 2024 294
Jun 2024 294
Jul 2024 294

Aurinia Pharmaceuticals other data

  • What's the price of Aurinia Pharmaceuticals stock today?

    One share of Aurinia Pharmaceuticals stock can currently be purchased for approximately $16.76.

  • When is Aurinia Pharmaceuticals's next earnings date?

    Unfortunately, Aurinia Pharmaceuticals's (AUP.TO) next earnings date is currently unknown.

  • Does Aurinia Pharmaceuticals pay dividends?

    No, Aurinia Pharmaceuticals does not pay dividends.

  • What is Aurinia Pharmaceuticals's stock symbol?

    Aurinia Pharmaceuticals Inc. is traded on the TSX under the ticker symbol "AUP.TO".

  • What is Aurinia Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Medical - Specialties industry.

  • How do i buy shares of Aurinia Pharmaceuticals?

    Shares of Aurinia Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Aurinia Pharmaceuticals have?

    As Jul 2024, Aurinia Pharmaceuticals employs 294 workers.

  • When Aurinia Pharmaceuticals went public?

    Aurinia Pharmaceuticals Inc. is publicly traded company for more then 24 years since IPO on 19 Sep 2000.

  • What is Aurinia Pharmaceuticals's official website?

    The official website for Aurinia Pharmaceuticals is auriniapharma.com.

  • Where are Aurinia Pharmaceuticals's headquarters?

    Aurinia Pharmaceuticals is headquartered at 1203-4464 Markham St, Victoria, BRITISH COLUMBIA.

  • How can i contact Aurinia Pharmaceuticals?

    Aurinia Pharmaceuticals's mailing address is 1203-4464 Markham St, Victoria, BRITISH COLUMBIA and company can be reached via phone at +1 250 708 4272.

Aurinia Pharmaceuticals company profile:

Aurinia Pharmaceuticals Inc.

auriniapharma.com
Exchange:

TSX

Full time employees:

294

Industry:

Medical - Specialties

Sector:

Healthcare

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.

1203-4464 Markham St
Victoria, BRITISH COLUMBIA V8Z 7X8

:
:
: